KdT Ventures

United States
Firm Location:United States • Austin, Texas • Chapel Hill, North Carolina
KdT Ventures Team
Photo of Rima Chakrabarti, Partner at KdT Ventures
Rima Chakrabarti
KdT Ventures·Partner
Sweet spot: $850K
Range: $700K - $1M
Investors in United States
Investors in Digital Health, Investors in Digital Health, Investors in Health & Hospital Services, Investors in Health & Hospital Services, Investors in Health IT, Investors in Health IT
Photo of Phil Grayeski, Partner at KdT Ventures
Phil Grayeski
KdT Ventures·Partner
Sweet spot: $850K
Range: $700K - $1M
Investors in Chapel Hill (NC)
Investors in BioTech, Investors in BioTech, Investors in Raleigh-Durham / Southeast US (Other Lists)
Photo of Mack Healy, Partner at KdT Ventures
Mack Healy
KdT Ventures·Partner
Sweet spot: $850K
Range: $700K - $1M
Investors in United States, Investors in Boston / New England, Investors in SF Bay Area (CA), Investors in San Diego (CA), Investors in Austin (TX), Investors in Houston (TX)
Investors in AgTech, Investors in AgTech, Investors in Analytics, Investors in Analytics, Investors in Austin (Other Lists), Investors in BioTech, Investors in BioTech, Investors in EnergyTech, Investors in EnergyTech, Investors in Health IT, Investors in Health IT, Investors in Material Science, Investors in Material Science, Investors in Pharmaceuticals, Investors in Pharmaceuticals
Photo of Cain McClary, Managing Partner at KdT Ventures
Cain McClary
KdT Ventures·Managing Partner
Sweet spot: $850K
Range: $700K - $1M
Investors in Austin (TX), Investors in United States, Investors in Asheville (NC), Investors in Boston (MA), Investors in SF Bay Area (CA)
Investors in AgTech, Investors in AgTech, Investors in AI, Investors in AI, Investors in Analytics, Investors in Analytics, Investors in Austin (Other Lists), Investors in BioTech, Investors in BioTech, Investors in EnergyTech, Investors in EnergyTech, Investors in Health IT, Investors in Health IT, Investors in Material Science, Investors in Material Science, Investors in Pharmaceuticals, Investors in Pharmaceuticals